High-Throughput CRISPR Screening Emerges as Key Tool to Separate Causal Aging Regulators From Correlative Markers
核心洞察
High-throughput CRISPR screening, both pooled and arrayed, is transforming functional genomics by enabling genome-wide interrogation of genes that drive or protect against cellular senescence (搜索).
A research topic call seeks studies using CRISPRko, CRISPRa, CRISPRi, and prime or base editing to identify druggable targets and synthetic lethal vulnerabilities in senescent cells.
Single-cell approaches such as Perturb-seq and CROP-seq, plus in vivo and 3D organoid screens, aim to map tissue-specific senescence regulators at single-cell resolution.
Aging research is pivoting toward functional genomics to resolve a persistent bottleneck: distinguishing genes that causally drive cellular senescence (搜索) from those that merely correlate with it. According to a research topic announcement on high-throughput CRISPR screening for aging regulators, transcriptomic and proteomic studies have identified numerous candidate genes linked to aging, yet separating causal regulators from correlative markers remains a major scientific challenge.
High-throughput CRISPR screening — both pooled and arrayed — has transformed functional genomics by enabling systematic, scalable, genome-wide interrogation of gene function across diverse biological contexts. When coupled with phenotypic readouts, selective pressures, or single-cell sequencing approaches such as Perturb-seq, these screens offer unprecedented resolution for mapping the regulatory networks that determine cellular lifespan and resilience to stress. Recent findings show CRISPR-based tools can uncover novel genetic determinants of senescence, rejuvenation, and organismal longevity, though large-scale integration across models and systems remains limited.
Screening Modalities Under Investigation
The research topic aims to accelerate progress at the intersection of genome editing and aging research by showcasing efforts to identify functional targets that drive or protect against senescence. It calls for studies employing CRISPR-based loss- and gain-of-function methodologies, including CRISPR knockout (CRISPRko), activation (CRISPRa), interference (CRISPRi), and prime or base editing.
Central questions framing the effort include which molecular pathways represent nodes of vulnerability in aging cells, how genome-wide CRISPR screens can be designed to distinguish pro-aging from protective factors, and which identified genes hold translational potential for novel senotherapeutic interventions.
Specific themes solicited include genome-wide CRISPR screens designed to identify positive and negative regulators of cellular senescence (搜索), replicative exhaustion, or stress-induced premature senescence (SIPS). Single-cell functional genomics approaches such as Perturb-seq and CROP-seq are sought to map transcriptional and epigenetic landscapes of aging at single-cell resolution, alongside in vivo and 3D organoid screening methodologies to identify tissue-specific senescence regulators and microenvironment-dependent aging mechanisms.
Additional areas include epigenetic CRISPR screening (CRISPRi/a) focused on histone modifications, DNA methylation, and chromatin remodeling factors that dictate the senescent program; screening of non-coding regulatory elements including lncRNAs, miRNAs, and enhancers that modulate longevity pathways and cellular quality control; and translational discovery based on CRISPR screens to identify druggable targets and synthetic lethal vulnerabilities in senescent cells. Computational and machine learning approaches for processing and modeling high-throughput CRISPR screening data in aging network analyses are also within scope.
Senescent Cells as a Therapeutic Target
Cellular senescence (搜索) occupies a central position in this research push. Senescent cells, often described as "zombie cells," stop dividing but resist dying, instead secreting inflammatory molecules that damage surrounding healthy tissue and accelerate aging. They accumulate with age and contribute to age-related diseases including arthritis, cardiovascular disease, and neurodegenerative disorders.
Research groups, including that of Dr. George Church at Harvard Medical School, are developing CRISPR/Cas9 (搜索) systems designed to reprogram or remove senescent cells to restore a more youthful cellular environment. The approach hinges on identifying unique genetic signatures of senescent cells, then designing CRISPR guides to either trigger apoptosis or reprogram the cells back into a healthy, functional state. Early studies in animal models have shown senescent cell removal leading to improvements in healthspan, including better cardiovascular function, reduced frailty, and extended lifespans.
Beyond senescence, other hallmarks of aging are being explored as CRISPR targets. Telomere attrition could potentially be addressed by lengthening telomeres (搜索) to extend the replicative lifespan of cells. Epigenetic alterations could be targeted with CRISPRa and CRISPRi tools that modify gene expression without cutting DNA, potentially resetting youthful epigenetic patterns. Mitochondrial dysfunction could be addressed by repairing mitochondrial DNA damage or enhancing expression of genes involved in mitochondrial biogenesis and function.
Delivery Remains a Critical Bottleneck
Translating these approaches into therapies faces substantial practical hurdles, chief among them delivery. Viral vectors, often adeno-associated viruses (AAVs) engineered to carry guide RNA and Cas enzyme into target cells, are efficient across various cell types and have a good safety profile — the basis for their use in approved sickle cell treatments — but are limited by genetic cargo size and potential immune responses. Non-viral methods include lipid nanoparticles (LNPs), which encapsulate CRISPR components and offer potentially lower immunogenicity and scalability, while electroporation and microinjection are generally restricted to ex vivo editing.
For systemic anti-aging treatments requiring targeting of cells across multiple organs, researchers are engineering new viral vectors and LNPs designed to home in on senescent cells or specific tissues, minimizing off-target effects. This area is described as a critical bottleneck whose resolution would significantly accelerate clinical translation.
Safety, Timeline, and Regulatory Path
The FDA's 2023 approval of Casgevy and Lyfgenia — the first CRISPR-based therapies, indicated for sickle cell disease (搜索) and transfusion-dependent beta-thalassemia (搜索) — validated CRISPR's precision, efficacy, and safety in a clinical setting. However, those treatments target specific genetic diseases, often with a single genetic fix, whereas aging is a far more complex, polygenic process.
Off-target edits remain a concern, particularly for systemic treatments affecting many cell types, and the long-term effects of altering fundamental genetic processes are largely unknown. Current research is primarily preclinical, conducted in mice, worms, and even non-human primates, to validate targets, optimize delivery, and assess side effects. Most experts believe widely available, FDA-approved CRISPR therapies specifically for reversing general aging are likely at least a decade — possibly two or three — away, with initial applications expected in specific age-related diseases with clear genetic components, such as Alzheimer's gene variants or therapies reprogramming cartilage cells in severe osteoarthritis (搜索).
Expert Perspectives and Computational Acceleration
The field encompasses diverse approaches. Dr. David Sinclair at Harvard Medical School is known for work on sirtuins (搜索) and NAD+ metabolism, pathways intersecting with epigenetic regulation and aging, while Dr. Juan Carlos Izpisúa Belmonte has explored cellular reprogramming and its potential to reverse hallmarks of aging in animal models. The consensus among these researchers is described as cautious optimism: enormous potential paired with a requirement for scientific rigor that "cannot be overstated."
Artificial intelligence is increasingly embedded in the pipeline. AI algorithms can sift through genomic and proteomic datasets to identify novel aging hallmarks and mutations, optimize guide RNA sequences while predicting off-target effects, model CRISPR component interactions to refine delivery, and tailor treatments to individual genetic makeup. Companies such as Google's DeepMind, with its AlphaFold protein-folding AI, illustrate the power of computational biology, with similar approaches promising to shorten development timelines.
Ethical questions accompany the science, including equitable access, the blurry line between therapy and enhancement for a universal process like aging, and germline modification, which is largely prohibited in many countries due to its irreversible nature and unknown long-term consequences. The stated goal remains extending healthspan — the period of life lived in good health — rather than eliminating death.